Huang Junchao, Zhang Jingwei, Xiao Haijun
Department of Orthopedics, Anhui University of Science and Technology Affiliated Fengxian Hospital, Shanghai, China.
Front Med (Lausanne). 2022 Jun 16;9:892593. doi: 10.3389/fmed.2022.892593. eCollection 2022.
Alterations of epigenetic modification patterns are potential markers of cancer. The current study characterized six histone modifications in osteosarcoma and identified epigenetically dysregulated long non-coding RNAs (epi-lncRNAs).
Multi-omics data were obtained from osteosarcoma cell line SJSA1 and a normal cell line. Differentially expressed lncRNAs (DElncRNAs) between osteosarcoma and normal skeletal muscle were analyzed using Limma. MACS2 was applied to identify the "peaks" modified by each histone in the cell. Promoters or enhancers of DElncRNA were overlapped with differential histone-modified regions (DHMR) to screen epi-lncRNAs. Univariate and multivariate Cox regression analysis were performed to detect the genes closely related to the prognosis of osteosarcoma and to construct risk models.
A total of 17 symbolic epi-lncRNA in osteosarcoma were screened, and 13 of them were differentially expressed between osteosarcoma and normal samples. Eight epi-lncRNAs were retained by Univariate Cox regression analysis. Four of these epi-lncRNAs were used to construct an epi-lncRNA signature. The risk score of each osteosarcoma sample in the high- or low-risk group was estimated according to the epi-lncRNA signature. The overall survival (OS) of the low-risk group was significantly better than that of the high-risk group. The area under the receiver operating characteristic (ROC) curve of the model was 0.79 and 0.82 for 1-, 3-, and 5-year OS, respectively.
Our results revealed the histone modification pattern in osteosarcoma and developed 4-epi-lncRNA signature to predict the prognosis of osteosarcoma, laying a foundation for the identification of highly specific epigenetic biomarkers for osteosarcoma.
表观遗传修饰模式的改变是癌症的潜在标志物。本研究对骨肉瘤中的六种组蛋白修饰进行了表征,并鉴定了表观遗传失调的长链非编码RNA(epi-lncRNA)。
从骨肉瘤细胞系SJSA1和正常细胞系中获取多组学数据。使用Limma分析骨肉瘤与正常骨骼肌之间差异表达的lncRNA(DElncRNA)。应用MACS2鉴定细胞中每种组蛋白修饰的“峰”。将DElncRNA的启动子或增强子与差异组蛋白修饰区域(DHMR)重叠以筛选epi-lncRNA。进行单变量和多变量Cox回归分析,以检测与骨肉瘤预后密切相关的基因并构建风险模型。
共筛选出17个骨肉瘤中的标志性epi-lncRNA,其中13个在骨肉瘤与正常样本之间差异表达。单变量Cox回归分析保留了8个epi-lncRNA。其中4个epi-lncRNA用于构建epi-lncRNA特征。根据epi-lncRNA特征估计高风险或低风险组中每个骨肉瘤样本的风险评分。低风险组的总生存期(OS)明显优于高风险组。该模型的受试者工作特征(ROC)曲线下面积在1年、3年和5年OS时分别为0.79和0.82。
我们的结果揭示了骨肉瘤中的组蛋白修饰模式,并开发了4-epi-lncRNA特征来预测骨肉瘤的预后,为鉴定骨肉瘤高度特异性的表观遗传生物标志物奠定了基础。